Zobrazeno 1 - 10
of 40
pro vyhledávání: '"Gregory B Lesinski"'
Autor:
Mark Yarchoan, Skylar Woolman, Lauren Dennison, Gregory B. Lesinski, Kayla Cruz, James M. Leatherman, Nilofer S. Azad, Elizabeth M. Jaffee, Aditya Mohan, Amanda Ruggieri
Publikováno v:
Cancer Immunol Res
MEK inhibition (MEKi) is proposed to enhance antitumor immunity but has demonstrated mixed results as an immunomodulatory strategy in human clinical trials. MEKi exerts direct immunomodulatory effects on tumor cells and tumor-infiltrating lymphocytes
Autor:
Edmund K. Waller, Maria Cardenas, Gregory B. Lesinski, Bassel F. El-Rayes, Jingru Zhu, Mohammad Y. Zaidi, Shuhua Wang, Brian S. Robinson, Michael B. Ware, Susan N. Thomas, Yuan Liu, Tenzin Passang Fnu, Shanmuganathan Chandrakasan, Sruthi Ravindranathan, Jian-Ming Li, Alan B. Frey, Rohan K. Dhamsania, Sanjeev Gumber, Anish Majumdar, Haydn T. Kissick
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundPaucity of T cells in the immune privileged tumor microenvironment (TME) of pancreatic ductal adenocarcinoma (PDAC) is a major reason that PDAC is refractory to immune checkpoint blockade.1 In this study, we show that human PDAC tumors over
Autor:
Juan M. Sarmiento, Shishir K. Maithel, Cameron Herting, Gregory B. Lesinski, Chrystal M. Paulos, Maggie Phillips, Megan M. Wyatt, Thomas A. Mace, Michael B. Ware, Bassel F. El-Rayes
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundPancreatic ductal adenocarcinoma (PDAC) is refractory to immunotherapy due in part to cellular cross-talk with cancer associated fibroblasts (CAFs). These interactions shape the microenvironment in a manner that is profoundly immunosuppress
Autor:
Matthew R. Farren, Yan Tong, Safi Shahda, Cameron Herting, Tanios Bekaii-Saab, Gregory B. Lesinski, Bert H. O'Neil, Bassel F. El-Rayes, Ziyue Liu, Christina Wu, Walid L. Shaib, Thomas A. Mace, Christopher McQuinn, Anne M. Noonan
Publikováno v:
Cancer Immunol Immunother
Modified FOLFOX6 is an established therapy for patients with metastatic colorectal cancer (mCRC). We conducted a single-arm phase Ib study to address the hypothesis that addition of pembrolizumab to this regimen could safely and effectively improve p
Autor:
Gregory B. Lesinski, Elad Sharon, Yuan Liu, Shishir K. Maithel, Subir Goyal, Brian Olson, Mark Yarchoan, Nilofer S. Azad, Helen X. Chen, Bassel F. El-Rayes, Amanda Ruggieri
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundBiliary tract cancers (BTCs) are aggressive malignancies often refractory to chemotherapy and immunotherapy. There is urgent need to identify novel, data-driven therapeutic targets to change the course of disease. It is also challenging to
Autor:
Cameron Herting, Yuchen Zhang, Kavita M. Dhodapkar, Shishir K. Maithel, Mohammad Y. Zaidi, Christina Wu, Mehmet Akce, Amanda Ruggieri, Bassel F. El-Rayes, Madhav V. Dhodapkar, Gregory B. Lesinski, Olatunji B. Alese, Juan M. Sarmiento, Michael B. Ware, Deon B. Doxie, Rafi Ahmed
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundPancreatic ductal adenocarcinoma (PDAC) has yet to widely benefit from T cell-targeted immunotherapy and displays universally poor prognosis. Thus, enhancing the activity of immunotherapy is a high priority. Our laboratory recently reported
Autor:
Xueliang Pan, Gregory B. Lesinski, Jeffrey Schlom, Renee N. Donahue, Thomas Olencki, Jacob Richards, Taylor R. Brooks, Volodymyr Karpa, Bonnie Paul, William E. Carson, Caroline Jochems, Megan C. Duggan, Elizabeth Foust, Susheela Tridandapani
Publikováno v:
Cancer Immunology, Immunotherapy. 65:1353-1364
Prime-boost vaccination with recombinant (r) vaccinia(V)-CEA(6D)-TRICOM (triad of co-stimulatory molecules B7.1, ICAM-1 and LFA-3) and rFowlpox(F)-CEA(6D)-TRICOM infect antigen-presenting cells and direct expression of co-stimulatory molecules. We hy
Publikováno v:
Journal for Immunotherapy of Cancer
Pancreatic ductal adenocarcinoma (PDAC) is plagued by a dismal 5-year survival rate, early onset of metastasis and limited efficacy of systemic therapies. This scenario highlights the need to fervently pursue novel therapeutic strategies to treat thi
Publikováno v:
Frontiers in Immunology
Frontiers in Immunology, Vol 9 (2018)
Frontiers in Immunology, Vol 9 (2018)
Pancreatic cancer has a dismal prognosis and effective treatment options are limited. It is projected to be the second most common cause of cancer related mortality in the United States by 2030 and there is urgent unmet need for novel systemic treatm
Autor:
Hannah M. Komar, Darwin L. Conwell, Zobeida Cruz-Monserrate, Phil A. Hart, Gregory B. Lesinski
Inflammatory and fibrotic events that drive chronic pancreatitis (CP) are likely orchestrated via signaling of soluble cytokines and chemokines systemically and within the pancreas. However, a comprehensive summary of the expression of such factors d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3df4011b0930a203a394f997a92faf3a
https://europepmc.org/articles/PMC5774026/
https://europepmc.org/articles/PMC5774026/